A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
Sponsor: Eli Lilly and Company
Terminated
Business decision based on the inability to enroll subjects into the trial
Other terminated trials from Eli Lilly and Company
Other Metastatic Breast Cancer trials with similar outcome
Listed as NCT04031885, this PHASE4 trial focuses on Metastatic Breast Cancer and remains terminated or withdrawn. Sponsored by Eli Lilly and Company, it has been updated 19 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
19 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE4
▶ Show 14 earlier versions
-
Dec 2021 — Dec 2022 [monthly]
Terminated PHASE4
-
Sep 2021 — Dec 2021 [monthly]
Terminated PHASE4
-
Jan 2021 — Sep 2021 [monthly]
Terminated PHASE4
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE4
Status: Suspended → Terminated
-
May 2020 — Nov 2020 [monthly]
Suspended PHASE4
Status: Recruiting → Suspended
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE4
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE4
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE4
-
Jan 2020 — Feb 2020 [monthly]
Recruiting PHASE4
-
Dec 2019 — Jan 2020 [monthly]
Recruiting PHASE4
-
Nov 2019 — Dec 2019 [monthly]
Recruiting PHASE4
-
Oct 2019 — Nov 2019 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Sep 2019 — Oct 2019 [monthly]
Not Yet Recruiting PHASE4
-
Aug 2019 — Sep 2019 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .